To compare the risk of major medical events in nursing home residents newly initiated on conventional or atypical antipsychotic medications (APMs). DESIGN: Cohort study, using linked Medicaid, Medicare, Minimum Data Set, and Online Survey Certification and Reporting data. Propensity score-adjusted proportional hazards models were used to compare risks for medical events at a class and individual drug level. 
A ntipsychotic medication (APM) use is widespread in nursing homes (NHs), 1, 2 especially in residents with behavioral disturbances. Up to one-third of all NH residents receive APMs, [3] [4] [5] [6] [7] mostly for the treatment of dementia-related behavioral disturbances, but serious safety concerns surround use of APMs in older adults with dementia-related psychoses. Based on randomized trials, the Food and Drug Administration (FDA) issued warnings of risks of stroke and transient ischemic events for risperidone (2003) followed by olanzapine and aripiprazole (2004) . 8 In 2005, the FDA issued warnings of excess mortality associated with the use of atypical APMs in older adults with dementia. 9 Moreover, a National Institutes of Health-sponsored clinical trial concluded that the adverse effects of atypical APMs offset their efficacy advantage in individuals with Alzheimer's disease 10 and that worsening of cognitive function is an additional risk of treatment with atypical APMs. 11 In June 2008, the FDA requested a similar boxed warning for conventional APMs 12 based on nonrandomized studies that used healthcare utilization databases. [13] [14] [15] The proposed mechanisms for the higher mortality remain speculative and include metabolic dysregulation; cardiac conduction disturbances; changes in blood pressure or heart rate, which may exacerbate preexisting heart failure; and sedation leading to aspiration with secondary pneumonia. 8, 16 Gait and movement disorders, confusion, delirium, excessive sedation, and orthostatic hypotension have also been associated with APM use and are well-established risk factors for falls and hip fractures. 17 An important next step in assessing the comparative safety of APMs is to examine the risk of these potential mediating cardiac and cerebrovascular events, infections, and hip fractures and to examine the extent to which these risks differ between classes and between individual APMs. These questions were addressed in a cohort of NH residents, who represent the most vulnerable and most widely treated segment of the elderly population.
METHODS

Data Source
The study cohort was drawn from a merged dataset of Medicaid and Medicare claims, the Minimum Data Set (MDS) and the Online Survey Certification and Reporting (OSCAR) system in 45 U.S. states (all except Arizona, Delaware, Nevada, Oregon, and Rhode Island) for 2001 to 2005. The claims data provided information on patient demographics, Medicaid eligibility, all physician services and hospitalizations, admissions to long-term care, and filled medication prescriptions. The MDS is a federally mandated health assessment tool used in NHs that captures information on physical, psychological, and psychosocial functioning; active clinical diagnoses; health conditions; and treatments and services and as such provides information on the resident's cognitive functioning and the presence of behavioral problems. OSCAR is a uniform database of NH regulatory reviews that is generated yearly for all NHs certified by the Centers for Medicare and Medicaid Services and includes operational and staffing characteristics and aggregate resident characteristics. Data are validated in onsite inspections that occur at least every 15 months.
Study Population
The current cohort consisted of residents aged 65 and older who were dually eligible for Medicare and Medicaid, who began treatment with an APM during a NH stay, and who had 6 months of continuous Medicaid coverage preceding the APM initiation date (index date). Incident use required the absence of any filled APM prescription in the 6 months before the index date. A new-user design was used to avoid underascertainment of events occurring soon after therapy begins 18 and to ensure that baseline covariates at study entry were assessed before APM treatment initiation. 19 Residents were excluded if they filled a prescription for a conventional and an atypical APM on the index date and if they had a preexisting diagnosis of schizophrenia, bipolar disorder, or cancer because they may have been receiving APM for reasons other than dementia-related behavioral problems (e.g., reduce nausea associated with chemotherapy or potentiate pain medications; Figure 1 ).
Antipsychotic Medications
Atypical APMs included risperidone, olanzapine, quetiapine, aripiprazole, and ziprasidone. Conventional APMs included haloperidol, thioridazine, chlorpromazine, perphenazine, and fluphenazine. Daily doses of the first dispensing of an APM were converted to chlorpromazineequivalent milligrams, [20] [21] [22] and the median daily dose in the population (50 mg) was used as a cutoff to assess the effect in strata of higher and lower doses for residents using tablets or caplets. For analyses at the class level, atypical APMs were chosen as the reference. For analyses at the level of individual APMs, the most commonly used APM in this population, risperidone, was chosen as the reference. Each resident was assigned to a specific APM and class of APM based on the medication prescribed on the index date; exposure was considered to be discontinued if there was a treatment gap of 14 days or longer.
Outcomes
Follow-up for end points extended up to 180 days. Outcomes considered included myocardial infarction (MI), cerebrovascular event (stroke or transient ischemic attack (TIA)), serious bacterial infection (bacteremia, septicemia, encephalitis, meningitis, endocarditis, myocarditis, pyelonephritis, septic arthritis, osteomyelitis, pneumonia, or opportunistic infection), and hip fracture. Outcomes were defined based on a hospitalization with a relevant primary or secondary International Classification of Diseases, Ninth Revision (ICD-9), diagnostic or procedure code (Table S1 ).
Patient and Nursing Home Characteristics
Patient characteristics were assessed during the 6 months preceding cohort entry. Sociodemographic characteristics included age, sex, race, education, and geographic region (state). Clinical characteristics were determined based on the most recent MDS assessment before treatment initiation, ICD-9 diagnostic and procedure codes associated with hospitalizations and physician visits, and medication use. Variables considered included psychiatric morbidity, cardiovascular morbidity, cerebrovascular disease, Parkinson's disease, epilepsy, diabetes mellitus, obesity, functional impairment, Charlson index, 23 and the use of healthcare services potentially predictive of adverse health outcomes in the short term (number of days hospitalized for any reason, number of distinct prescription drugs excluding APMs). 24 NH characteristics, which may be correlated with care processes and risk of adverse health outcomes, were obtained from OSCAR. These included variables such facility size, occupancy rate, availability of special care units, staffing levels, ownership, resident characteristics (proportion with dementia, depression), and quality indicators (e.g., proportion of residents bed-or chair-bound).
Data Analysis
Rates of the various outcomes during follow-up were calculated, with follow-up censored at the time of treatment discontinuation or switch to a medication belonging to a different APM class (class-level analysis) or a switch to a different medication (individual-APM analysis). Other censoring events included death and hospitalizations of 10 days or longer for reasons other than the outcomes of interest.
Unadjusted age-, sex-, and calendar year-adjusted and multivariate-adjusted proportional hazards models were fit for pairwise comparisons against atypical APMs (classlevel analysis) and risperidone (individual APM analysis). No violations of the assumption of proportional hazards were detected based on graphical approaches and goodness-of-fit tests. For more-efficient estimation, propensity score (PS) adjustment was used to balance measured risk factors for the outcomes between drug user groups. 25 PSs at treatment initiation were derived from predicted probabilities estimated in logistic regression models that contained all of the covariates listed earlier, and Cox models were stratified across deciles of the PS. Models were run separately in strata defined according to diagnoses of dementia, behavioral disturbances, and delirium and according to dose, dividing each drug user group into those taking 50 mg or less or more than 50 mg of chlorpromazine equivalents.
In secondary analyses, high-dimensional PS (hdPS) adjustment was used. 26 A limitation of standard approaches to confounding adjustment that hdPS attempts to overcome is their reliance on the investigator being able to specify all factors that may confound a causal association between medication and outcome. The hdPS algorithm evaluates thousands of diagnoses, procedures, and pharmacy claim codes, as well as clinical (MDS) and facility (OSCAR) characteristics (referred to as data dimensions), to identify and prioritize those covariates that serve as proxies for unmeasured confounders. Specifically, the 200 most-prevalent codes in each data dimension were identified, and from these, 500 likely confounders were selected based on their prevalence and potential for confounding in the study population. These empirically identified confounders are combined with investigator-identified covariates (sociodemographic variables and general indicators of comorbidity) to improve confounding adjustment. A dose-response analysis was conducted by comparing the risk of the various event types in residents treated with high-and low-dose APMs for all APMs combined.
Adjustments for multiple comparisons were not considered. 27 Rather than interpreting results qualitatively in terms of what is or is not statistically significant (through use of P-values or confidence intervals as a pseudo significance test), results were interpreted quantitatively to enhance the assessment of competing explanations, such as uncontrolled confounding. This approach keeps separate the two components of estimation-effect size and precision-instead of confusing them in a single qualitative assessment, namely significance testing.
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RESULTS
Of the 83,959 NH residents included in the study cohort, 8.9% were prescribed a conventional APM and 91.1% an atypical APM. Residents in the conventional APM group were more likely to be male and nonwhite than those in the atypical APM group. They were more likely to have cardiovascular disease and less likely to have psychiatric comorbidities. Both groups were comparable in terms of severity of cognitive and functional impairment and presence of diagnosed behavioral problems. Residents using conventional APMs had lower rates of antidepressant and Residents treated with conventional APMs were less likely than patients treated with atypical APMs to reside in a NH located in the Northeast or in an urban setting (Table 1) . In residents initiating conventional APMs, haloperidol (87%) was by far the most widely used APM. In those initiating atypical APMs, risperidone (40%), olanzapine (33%), and quetiapine (23%) were used most frequently. Ziprasidone and aripiprazole, which were introduced in 2001 and 2002, respectively, each represented less than 3% of atypical APM use in the study population. Overall, residents initiating different atypical APMs resembled one another in terms of demographic and clinical characteristics. Residents treated with risperidone had slightly fewer recorded depression diagnoses and less use of antidepressants and other psychotropic medications. Residents treated with quetiapine were more likely to have Parkinsonism than the other groups (Table 1) .
Class-Level Analyses
The overall mean follow-up since cohort entry was 45 days for residents initiating conventional APMs and 96 days for those initiating atypical APMs; 13% of residents initiating conventional APMs died, compared with 10% of those initiating atypical APMs. Half of the residents were censored because of a treatment switch or discontinuation and 15% because of hospitalization for reasons unrelated to the outcomes. For all event types considered, residents initiating conventional APMs had higher unadjusted rates than those initiating atypical APMs ( Table 2) . Results of the PS-adjusted Cox regression analyses indicate that residents initiating conventional APMs were at greater risk of serious bacterial infection (hazard ratio (HR) = 1.37, 95% confidence interval (CI) = 1.17-1.62) and at lower risk of cerebrovascular events (HR = 0.81, 95% CI = 0.65-1.01). Findings further suggest that residents initiating conventional APMs may be at greater risk of MI (HR = 1.23, 95% CI = 0.82-1.82), hip fracture (HR = 1.27, 95% CI = 0.94-1.72), and pneumonia (HR = 1.28; 95% CI = 0.87-1.88), but these associations were imprecisely estimated. Results for the conventional PS and the hdPS analyses were consistent (Table 3) . Analyses stratified according to dose confirmed the findings for serious bacterial infection (PS-adjusted HR = 1.42, 95% CI = 1.10-1.84 for low dose, PSadjusted HR = 1.47, 95% CI = 1.13-1.91 for high dose) and indicated that the high-dose category determines the lower risk of cerebrovascular events (HR = 1.01, 95% CI = 0.71-1.42 for low dose, HR = 0.62, 95% CI = 0.42-0.93 for high dose). Results for the other outcomes are not presented because of the small (<10) event numbers in some dose strata and resulting unstable estimates.
Individual-APM Analyses
All associations were estimated with risperidone as the reference group. In view of the fact that 87% of residents initiating conventional APMs were treated with haloperidol, the findings for haloperidol mirror those of the class-level analyses shown above.
The mean follow-up in days since cohort entry was 94 for risperidone, 97 for olanzapine, 96 for quetiapine, 99 for aripiprazole, and 92 for ziprasidone. Results from hdPS-adjusted analyses tended to be somewhat closer to the null than those from conventional PS-adjusted analyses. In residents initiating olanzapine, the associations for MI (hdPS-adjusted HR = 1.03, 95% CI = 0.81-1.32), serious bacterial infections (hdPS-adjusted HR = 0.99, 95% CI = 0.89-1.09), and hip fracture (hdPS-adjusted HR = 1.08, 95% CI = 0.91-1.29) were near null. The HR was 0.91 (95% CI = 0.81-1.02) for cerebrovascular events and 1.20 (95% CI = 0.94-1.53) for pneumonia (Table 3) . In residents initiating quetiapine, the associations for MI (HR = 1.02, 95% CI = 0.77-1.34) and pneumonia (HR = 1.05, 95% CI = 0.78-1.42) were near null. Residents treated with quetiapine had a lower risk of bacterial infection (HR = 0.83, 95% CI = 0.73-0.94). The HR was 0.89 (95% CI = 0.79-1.02) for cerebrovascular events and 1.17 (95% CI = 0.96-1.43) for hip fracture (Table 3) . There was no evidence of effect measure modification according to dose for olanzapine or quetiapine (Figure 2A) .
Given the few residents treated with aripiprazole and ziprasidone during the study period, there was insufficient information to draw meaningful conclusions for most event types, except a near null association for cerebrovascular events and hip fracture (Table 3) .
There was no evidence of effect measure modification according to the presence of dementia, behavioral disturbances, or delirium for the class level or individual APM analyses (data not shown). 
Dose-Response Analyses
When comparing the risk of major medical events in residents treated with high (>50 mg chlorpromazine equivalents) versus low ( 50 mg) doses of all APMs combined, greater risk was observed with high doses for pneumonia (hdPS-adjusted HR = 1.24, 95% CI = 1.00-1.53) and hip fracture (1.28, 95% CI = 1.10-1.49). The associations for MI (1.09, 95% CI = 0.89-1.35), cerebrovascular events (1.11, 95% CI = 1.00-1.22), and serious bacterial infections (1.09, 95% CI = 0.99-1.19) were weaker, but still pointed toward greater risk ( Figure 2B, Panel A) . The association for the risk of hospitalization between high and low doses for any of the events considered was 1.12 (95% CI = 1.05-1.19). Results were similar when restricted to all atypical APMs ( Figure 2B, Panel B) . Results for users of conventional APMs are not presented owing to the small event numbers.
DISCUSSION
In this population of Medicaid-eligible NH residents, risks of serious bacterial infections, MI, and hip fracture that were higher and risks of cerebrovascular events that were lower were observed in residents initiating conventional APMs than in those initiating atypical APMs. Little variation in event risk was observed between individual atypical APMs except for a somewhat lower risk of cerebrovascular events with olanzapine and quetiapine than with risperidone and a lower risk of serious bacterial infections and possibly a higher risk of hip fracture with quetiapine than with risperidone. A dose-response relation was observed for all event types for all APMs combined.
Conventional APMs have been associated with greater risk of cardiovascular death than atypical APMs. 35 The current findings are suggestive of greater risk of MI leading to hospitalization for conventional APMs. Although danzapine shares with risperidone warnings related to risk of stroke, 8 the current findings suggest that the risk of stroke or TIA with olanzapine is lower than with risperidone. A similar risk of stroke or TIA was found for aripiprazole and risperidone, but the data were insufficient to examine the effect of dose. The greater risk of serious bacterial infection associated with use of conventional than atypical APMs was consistent with an earlier report of greater risk of death and hospitalization due to infection 35 but stands in contrast to the greater risk of pneumonia observed in individuals using atypical than conventional APMs in two case-control studies of community-dwelling elderly adults. 36, 37 Current evidence of the differential risk of hip fracture between conventional and atypical APMs is still inconclusive, [38] [39] [40] [41] and the risks in individuals initiated on different atypical APMs have not previously been examined. It is believed that differences in receptor-affinity profile within this heterogeneous class of drugs may explain differences in side-effect profiles between APMs, but the specific associations are not well understood. 42 Multiple approaches were used in the design and analysis of the study to reduce the possibility of confounding, including an incident-user design, implementation of different methods to mitigate confounding by predefined covariates and by proxies for unobserved factors (hdPS adjustment), prospective follow-up of the population for the outcomes of interest, and documentation of and accounting for changes in exposure status.
Despite these strengths, the current analyses should be interpreted in the context of several limitations. First, as with all nonrandomized studies, residual confounding by indication is a factor to consider as an alternative explanation of the findings. This would occur if residents who were frail and at risk of undesirable health outcomes were more or less likely to be prescribed certain APMs than others. Confounder information derived from claims data was supplemented with clinical assessment data from the MDS. Because NH residents may be at greater risk of adverse health outcomes simply by being admitted to a facility with poor quality indicators, 43 potential NH quality indicators were accounted for through use of the OSCAR database, which reflects findings from state inspections and complaint investigations. Nevertheless, if the presence or severity of important clinical conditions or quality-of-care measures were incompletely captured, this could lead to residual confounding. High-dimensional proxy adjustment based on PS techniques was therefore used in an effort to further improve confounding control compared with adjustment limited to predefined covariates. 26 Second, there is likely to be underascertainment of the outcomes (e.g., not all pneumonia cases in NH residents will require hospitalization). As long as the misclassification is nondifferential and the specificity of the disease definition is high (ensured through the implementation of strict disease definitions), the relative effect measures should be unbiased. 44 Third, there is potential for misclassification of exposure status. This would occur if there is a lack of consumption of filled prescriptions (e.g., due to nonadherence or occasional use), although adherence is expected to be high in a population of NH residents that is closely monitored. Nonetheless, occasional (as needed) use might be an important source of misclassification because it is imperfectly captured in claims data. Fourth, residents were classified into low-and high-dose groups based on the initial prescription filled. In case of dose titration, this could have resulted in exposure misclassification in the analyses stratified according to dose. The second and last prescription filled before end of follow-up were verified, and the dose assignment remained unchanged for more than 90% of the residents, suggesting that this is not an important source of misclassification. Fifth, the known potential for drug intolerance or treatment failure may lead to drug discontinuation and thus informative censoring. This could make treatment switches or discontinuation a predictor for adverse health outcomes that would not be observed in an as-treated analysis, introducing bias toward the null. To minimize this potential bias, a 30-day grace period was allowed for at the time of treatment change. Any outcomes observed during this time period were still attributed to the initial exposure. Varying the length of the grace period did not meaningfully affect the findings. Finally, by not imposing the presence of a recorded dementia diagnosis as an inclusion criterion, it is possible that some residents in the cohort received APMs for reasons other than dementia-related behavioral problems. Given the underrecording of dementia diagnoses in elderly adults with multiple comorbidities and the exclusion of individuals with a schizophrenia or bipolar diagnosis, it is expected that this number would be small however. Moreover, analyses stratified according to the presence of a recorded dementia diagnosis showed no evidence of effect measure modification.
The fact that no previous studies have directly evaluated the relationship between different APMs and risk of multiple adverse health outcomes in routine care, the consideration of dose, the large study size used, the focus on the most vulnerable and most widely treated segment of the elderly population, and the access to detailed clinical and quality-of-care-related variables make this investigation valuable to clinical practice. The findings provide new information concerning the comparative safety of the antipsychotic treatment options available for individuals with dementia-related behavioral problems. The observed associations lend further support to the premise that conventional APMs are less safe than atypical APMs in elderly adults with dementia-related behavioral symptoms and generally should not be used in this population. Overall, little variation existed between individual atypical APMs, but for some event types, effect estimates ranged from about 10% to 17% on the relative scale. Although these differences are small, they are not inconsequential in a vulnerable population of older nursing home residents already burdened by an array of medical illnesses and complex medication regimens. While awaiting confirmation of these findings, it therefore seems prudent for clinicians to evaluate a given drug's risk profile against an individual's vulnerabilities when selecting a specific APM and dose and to closely monitor its safety.
